Role of Extracellular Vesicles in Epithelial Ovarian Cancer: A Systematic Review.
Antineoplastic Agents
/ therapeutic use
Carcinoma, Ovarian Epithelial
/ diagnosis
Cell Communication
/ drug effects
Cell Line, Tumor
Drug Resistance, Neoplasm
/ genetics
Early Detection of Cancer
Epithelial-Mesenchymal Transition
/ genetics
Extracellular Vesicles
/ genetics
Female
Gene Expression Regulation, Neoplastic
Humans
Lymphatic Metastasis
MicroRNAs
/ genetics
Ovarian Neoplasms
/ diagnosis
RNA, Neoplasm
/ genetics
Signal Transduction
Tumor Escape
Tumor Microenvironment
/ genetics
epithelial mesenchymal transition
extracellular vesicles
immunological escape
microRNAs
ovarian cancer
tumor microenvironment
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
19 Nov 2020
19 Nov 2020
Historique:
received:
30
10
2020
revised:
14
11
2020
accepted:
15
11
2020
entrez:
24
11
2020
pubmed:
25
11
2020
medline:
5
3
2021
Statut:
epublish
Résumé
Extracellular vesicles (EVs) are a heterogeneous group of cell-derived submicron vesicles released under physiological or pathological conditions. EVs mediate the cellular crosstalk, thus contributing to defining the tumor microenvironment, including in epithelial ovarian cancer (EOC). The available literature investigating the role of EVs in EOC has been reviewed following PRISMA guidelines, focusing on the role of EVs in early disease diagnosis, metastatic spread, and the development of chemoresistance in EOC. Data were identified from searches of Medline, Current Contents, PubMed, and from references in relevant articles from 2010 to 1 April 2020. The research yielded 194 results. Of these, a total of 36 papers, 9 reviews, and 27 original types of research were retained and analyzed. The literature findings demonstrate that a panel of EV-derived circulating miRNAs may be useful for early diagnosis of EOC. Furthermore, it appears clear that EVs are involved in mediating two crucial processes for metastatic and chemoresistance development: the epithelial-mesenchymal transition, and tumor escape from the immune system response. Further studies, more focused on in vivo evidence, are urgently needed to clarify the role of EV assessment in the clinical management of EOC patients.
Identifiants
pubmed: 33228245
pii: ijms21228762
doi: 10.3390/ijms21228762
pmc: PMC7699467
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
MicroRNAs
0
RNA, Neoplasm
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Références
Methods Mol Biol. 2017;1660:221-232
pubmed: 28828660
Sci Rep. 2017 Jul 28;7(1):6767
pubmed: 28754913
J Proteomics. 2019 Jul 30;204:103403
pubmed: 31170500
Int J Mol Sci. 2019 Aug 18;20(16):
pubmed: 31426571
Int J Clin Exp Pathol. 2015 May 01;8(5):5062-70
pubmed: 26191200
J Cell Mol Med. 2012 Feb;16(2):337-48
pubmed: 21435174
Int J Biol Sci. 2018 Nov 1;14(14):1960-1973
pubmed: 30585260
Biomed Res Int. 2015;2015:701390
pubmed: 26583126
Transl Cancer Res. 2015 Jun;4(3):256-269
pubmed: 26213686
IUBMB Life. 2011 Jul;63(7):538-46
pubmed: 21698758
Cytometry A. 2016 Feb;89(2):196-206
pubmed: 26484737
J Proteomics. 2013 Mar 27;80:171-82
pubmed: 23333927
J Extracell Vesicles. 2018 Jan 23;7(1):1422675
pubmed: 29410779
Gynecol Oncol. 2015 Apr;137(1):143-51
pubmed: 25579119
J Am Heart Assoc. 2017 Mar 8;6(3):
pubmed: 28275069
Thromb Haemost. 2014 Jun;111(6):1009-14
pubmed: 24553954
Cancer Lett. 2017 May 1;393:60-67
pubmed: 28216373
Diabetes Metab Res Rev. 2017 Nov;33(8):
pubmed: 28753251
FASEB J. 2017 May;31(5):1856-1866
pubmed: 28100645
Circ Res. 2017 May 12;120(10):1632-1648
pubmed: 28495994
Carcinogenesis. 2014 Sep;35(9):2113-20
pubmed: 24925027
Am J Med Sci. 2019 Oct;358(4):256-267
pubmed: 31353030
Cancer Res. 2016 Apr 1;76(7):1770-80
pubmed: 26992424
Cancer Immunol Res. 2018 Dec;6(12):1578-1592
pubmed: 30396909
Mol Cancer. 2019 Aug 13;18(1):124
pubmed: 31409361
Oncol Rep. 2016 Dec;36(6):3472-3478
pubmed: 27748885
Biochem Soc Trans. 2018 Oct 19;46(5):1073-1082
pubmed: 30242120
Nat Commun. 2019 Jul 5;10(1):3000
pubmed: 31278254
J Thromb Haemost. 2013 Jun;11 Suppl 1:36-45
pubmed: 23809109
Tumour Biol. 2014 Feb;35(2):1051-6
pubmed: 24061637
BMC Cancer. 2019 Nov 12;19(1):1095
pubmed: 31718609
Cancers (Basel). 2018 Oct 31;10(11):
pubmed: 30384500
Oncotarget. 2017 Oct 6;8(56):96035-96047
pubmed: 29221185
J Cell Biol. 2010 Sep 20;190(6):1079-91
pubmed: 20837771
J Oncol. 2019 Nov 18;2019:5879616
pubmed: 31827511
Cancers (Basel). 2019 Aug 10;11(8):
pubmed: 31405096
Nat Rev Mol Cell Biol. 2005 May;6(5):376-85
pubmed: 15852042
J Ovarian Res. 2018 Sep 15;11(1):81
pubmed: 30219071
Apoptosis. 2003 Jan;8(1):61-70
pubmed: 12510153
Int J Mol Sci. 2020 Mar 19;21(6):
pubmed: 32204473
Cells. 2020 Mar 27;9(4):
pubmed: 32230983
Dev Cell. 2011 Oct 18;21(4):708-21
pubmed: 21962903
Nat Protoc. 2019 Apr;14(4):1027-1053
pubmed: 30833697
J Extracell Vesicles. 2012 Apr 16;1:
pubmed: 24009880
Dis Markers. 2017;2017:1575374
pubmed: 28325957
Methods Mol Biol. 2017;1545:21-33
pubmed: 27943204
Eur Rev Med Pharmacol Sci. 2016 May;20(10):2004-10
pubmed: 27249598
Cancer. 2018 Feb 1;124(3):580-586
pubmed: 29112229
Front Immunol. 2018 Jul 06;9:1583
pubmed: 30034401
J Oncol. 2019 Jun 9;2019:1639854
pubmed: 31281356
Front Pharmacol. 2019 Jan 22;10:7
pubmed: 30723407
Oncotarget. 2016 Feb 23;7(8):8839-49
pubmed: 26814433
Methods. 2020 May 1;177:35-49
pubmed: 32035230
Nat Commun. 2017 Mar 06;8:14470
pubmed: 28262727
Cancer Discov. 2012 Dec;2(12):1100-8
pubmed: 23171795
Onco Targets Ther. 2018 Jan 09;11:291-299
pubmed: 29386907
FASEB J. 2013 Oct;27(10):4169-83
pubmed: 23804239
Front Immunol. 2014 Sep 16;5:442
pubmed: 25278937
J Vis Exp. 2014 Oct 19;(92):e51623
pubmed: 25350417
J Endocrinol Invest. 2020 Apr 25;:
pubmed: 32335856
J Exp Clin Cancer Res. 2019 Jul 18;38(1):317
pubmed: 31319863
Transfus Apher Sci. 2015 Oct;53(2):110-26
pubmed: 26603057
Nanomedicine. 2011 Dec;7(6):780-8
pubmed: 21601655
Sci Rep. 2019 Apr 15;9(1):6051
pubmed: 30988318
Oncol Rep. 2011 Mar;25(3):749-62
pubmed: 21181093
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt B):186-196
pubmed: 26278673
Cell Biol Int. 2014 Sep;38(9):1076-9
pubmed: 24798520
Cytometry B Clin Cytom. 2016 Jul;90(4):326-36
pubmed: 26606416
Cancers (Basel). 2019 Jan 08;11(1):
pubmed: 30626032
J Extracell Vesicles. 2019 Apr 26;8(1):1608786
pubmed: 31069027
J Extracell Vesicles. 2013 Aug 27;2:
pubmed: 24223257
Colloids Surf B Biointerfaces. 2011 Oct 1;87(1):146-50
pubmed: 21640565
Pharmacol Rev. 2012 Jul;64(3):676-705
pubmed: 22722893
Sci Rep. 2018 Feb 15;8(1):3071
pubmed: 29449691
J Biol Chem. 1998 Aug 7;273(32):20121-7
pubmed: 9685355
Dis Markers. 2017;2017:9653194
pubmed: 28607529
FASEB J. 2020 Mar;34(3):3616-3630
pubmed: 31957088
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Int J Mol Sci. 2017 May 29;18(6):
pubmed: 28555055
Cancer Lett. 2018 Oct 28;435:80-91
pubmed: 30098399
Eur J Immunol. 2019 Oct;49(10):1457-1973
pubmed: 31633216
Mol Oncol. 2018 Nov;12(11):1935-1948
pubmed: 30107086
J Ovarian Res. 2018 Mar 2;11(1):20
pubmed: 29499737
Cytometry A. 2014 Sep;85(9):756-70
pubmed: 24903900
Semin Cancer Biol. 2014 Oct;28:3-13
pubmed: 24769058
Traffic. 2009 Oct;10(10):1528-42
pubmed: 19682328
Cancer Chemother Pharmacol. 2018 Jan;81(1):17-38
pubmed: 29249039
BMC Cancer. 2012 Sep 24;12:421
pubmed: 22998595
Methods Mol Biol. 2017;1545:43-54
pubmed: 27943206
Int J Mol Sci. 2020 Oct 23;21(21):
pubmed: 33114229
Nanoscale. 2018 Mar 15;10(11):5318-5324
pubmed: 29504612
Clin Chem Lab Med. 2019 Jun 26;57(7):1053-1062
pubmed: 30422797
Cancer Res. 2010 Feb 15;70(4):1668-78
pubmed: 20124479
Bioengineering (Basel). 2019 Jan 16;6(1):
pubmed: 30654439
J Immunol. 2001 Jun 15;166(12):7309-18
pubmed: 11390481
BMC Cancer. 2018 Nov 5;18(1):1065
pubmed: 30396333
J Extracell Vesicles. 2016 Oct 31;5:32945
pubmed: 27802845
Int J Mol Sci. 2019 Sep 27;20(19):
pubmed: 31569731
Clin Cancer Res. 2003 Nov 1;9(14):5113-9
pubmed: 14613988
BMC Med Genomics. 2019 Nov 4;12(1):151
pubmed: 31684971
Mol Cell Proteomics. 2019 May;18(5):865-875
pubmed: 30760538
PLoS One. 2017 Jan 23;12(1):e0170628
pubmed: 28114422